ISCP 2018, Kyoto – Full Program

Opening Remarks

Koji Hasegawa, Chair of 23rd ISCP Kyoto 2018, President of ISCP

Future Pharmacotherapy for Atherosclerosis: Basic Science for the Clinician

Kensuke Noma, Hiroshima, Japan
Morihiro Matsuda, Kure, Japan

Tatsuya Sawamura, Nagano, Japan: Modified Lipoproteins and LOX-1 in Cardiovascular Disease
Noboru Ashida, Kyoto, Japan: Role of inflammatory signaling in vascular calcification
Tetsuya Matoba, Fukuoka, Japan: Ezetimibe ameliorates coronary endothelial dysfunction through decreases in oxysterols
Koh Ono, Kyoto, Japan: SREBF1/MicroRNA-33b axis exhibits potent effect on unstable atherosclerotic plaque formation in vivo

Joint Panel Discussion
ESC Working Group on Cardiovascular Pharmacotherapy:
Cardiac and Systemic Linkage for the Control of Hypertension

Heinz Drexel, Austria
Koji Hasegawa, Kyoto, Japan
Thomas Kahan, Sweden: Hypertensive heart disease
Stefan Agewall, Norway: Effective at last – The new glucose-lowering drugs that reduce CV events
Celso Amodeo, Brazil: Resistant hypertension
Junichi Oyama, Saga, Japan: Sleep apnea syndrome

Seminar supported by GSK: Pulmonary Hypertension

Atsushi Nakano, Japan
Carlos Jardim, Brazil
Hiromi Matsubara, Okayama, Japan

Panel Discussion:
Prevention of Atherosclerotic Events by Targeting Lipid Metabolism and Inflammation

Juan Carlos Kaski, UK
Celso Amodeo, Brazil
Heinz Drexel, Austria: PCSK9-inhibitors for which patient?
Video available >
Masaaki Kawashiri, Kanazawa, Japan: Familiar Hypercholesterolemia
Video available >
Alberto Lorenzatti, Argentina: Anti-inflammatory drugs: niche treatment or broad application?
Video available >

Meet the Experts – pharmacotherapy challenges

Koji Hasegawa and Juan Carlos Kaski
George Dan, Thomas Kahan, Antoni Martinez Rubio, Felipe Martìnez.
What is the best strategy for the management of HFpEF?
Should we use a same type of anticoagulant for all patients with AF?
PCSK9 Inhibitors: Indications and timing
Are β-blockers useful for the management of systemic hypertension?

Joint WHF/ISCP Plenary Session:
Global Cardiovascular Risk Management to Achieve ‘25 by 25’

Chairs and Modulators:
Jean-Luc Eiselé, CEO, World Heart Federation
Koji Hasegawa, President, ISCP
Opening Remarks:
Chuichi Kawai, Past President of World Heart Federation
Speakers and Discussants:
Katsuyuki Miura, Shiga, Japan:Global Epidemiology in Cardiovascular Risk Factors
Alvaro S. Liprandi, Argentina: Roadmaps to Achieve ‘25 by 25’ ─Global and Regional Coalitions─
Shinji Koba, Tokyo, Japan: The Role of Exercise for Cardiovascular Prevention
Maki Komiyama, Kyoto, Japan: Smoking and depression in Cardiovascular Disease
Edgardo Escobar, Chile: Telemedicine to Reduce Mortality in Heart Attacks

Henry N. Neufeld Memorial Award Lecture:

Lina Badimon, Catalan Institute of Cardiovascular Sciences (ICCC), Spanish National Research Council (CSIC)
Precision Medicine: Molecular Phenotyping in Cardiovascular Pharmacotherapy
Video available>

Reprograming and Regeneration of the Heart: Basic Science for the Clinician

Tatsuya Morimoto, Shizuoka Japan
Shuhei Tomita, Osaka, Japan
Teruhisa Kawamura, Kyoto, Japan: Dissecting the Process of Metabolic Shift during iPS Cell Reprogramming from Fibroblasts
Junko Kurokawa, Shizuoka, Japan: Electrophysiological maturation of human iPS-derived cardiomyocytes
Masaki Ieda, Ibaraki, Japan: Direct Cardiac Reprogramming and Heart Regeneration
Takeru Makiyama, Kyoto, Japan: Modelling long-QT syndrome with human iPS cells and development of new pharmacotherapies

Joint session of ISCP and ISCMF
Recent Advances in Cardiomyopathies, Myocarditis and Heart Failure

Mario Maranhao, Brazil
Peter Schultheiss, Germany
Akira Matsumori, Kyoto, Japan: New biomarkers of inflammation and cardiovascular risk
Peter Liu, Ottawa, Canada: Genetic and Protein Biomarkers in the Diagnosis and Management of Cardiomyopathies and Heart Failure
Andre Keren, Israel: Clinical implications of the new European definition of dilated cardiomyopathy
Leslie Cooper, USA: The Evolving Role for Nuclear Imaging in Unexplained Cardiomyopathy
Peter Schultheiss, Germany: Modelling long-QT syndrome with human iPS cells and development of new pharmacotherapies

Up-to-date Topics of Atrial Fibrillation and Anti-coagulant Therapy

Felipe Martinez, Argentina
Masaharu Akao, Kyoto, Japan: Risk stratification of atrial fibrillation in Asia
Dalmo Moreira, Brazil: Is there a role for the nonvit K antagonist in the prevention of atrial fibrillation? 

Pharmacotherapy and Life-style Modification for Heart Failure: the Present and the Future

Shigetake Sasayama, Kyoto, Japan
Yasushi Fujio, Osaka, Japan
Sang Hong Baek, Korea: Myocardial fibrosis and new options for treatment
Felipe Martinez, Argentina: New drugs in heart failure: more of the same or the beginning of a new era?
Takuya Kishi, Fukuoka, Japan: Cardiac linkage with brain and autonomic nervous system

Cardiovascular Imaging Guiding Pharmacotherapy

Alberto Lorenzatti, Argentina
Masataka Sata, Tokushima, Japan
Augusto Gallino, Switzerland: Role of imaging in developing new drugs
Takashi Akasaka, Wakayama, Japan: Optical coherence tomography
Mitsuyasu Terashima, Aiti, Japan: Intravascular Ultrasound

Panel Discussion:
Controversies in Anti-coagulant Therapy in Atrial Fibrillation and Venous Thromboembolism

George A. Dan, Romania
Takanori Ikeda, Tokyo, Japan
Ali Oto, Turkey: Risk stratification of stroke in AF
Antoni Martinez-Rubio Barcelona, Spain: DOAC for AF
Shinji Hisatake, Tokyo, Japan: DOAC for VTE

Panel Discussion
Treatment of Atrial Fibrillation: the Place of Antiarrhythmic Drugs

Ali Oto, Turkey
Atsushi Sugiyama, Tokyo, Japan
George A. Dan, Romania: Antiarrhythmic drugs
Naohiko Takahashi, Oita, Japan: Inflammation in AF

Joint Workshop with Asian Pacific Society of Cardiology (APSC)
Prediction and Prevention of Sudden Cardiac Death and Syncope

Jiunn-Lee Lin, Taiwan (from APSC)
Nannette R. Rey, Philippine (from ISCP)
Anca Dan, Romania: Syncope: Diagnosis and risk stratification
Naohiko Takahashi, Oita, Japan: Sudden cardiac death in J-wave syndrome
Takanori Ikeda, Tokyo, Japan: Prediction of sudden cardiac death

Award Ceremony for Best Abstract Presentation

Closing Remarks

Augusto Gallino, Chair, 24th ISCP Switzerland 2019

Drug Management of Coronary Vasospasm, Microvascular Angina and Takotsubo Cardiomyopathy

Masatoshi Fujita, Kyoto, Japan
Masataka Sata, Tokushima, Japan
Juan Carlos Kaski, UK: Microvascular angina
Sang Hong Baek, Korea: Coronary vasospasm
Yoshihiro Akashi, Kanagawa, Japan: Takotsubo cardiomyopathy

Joint Symposium with Asian Pacific Society of Cardiology (APSC)
Biomarkers to Predict Acute Coronary Syndrome, Atherosclerosis and Heart Failure

San-Jou Yeh, Taiwan (from APSC)
Jorge A. Sison, Philippine (from ISCP)
Bernard MY Cheung, Hong Kong: Biomarkers for acute coronary syndrome – are they good enough?
Augusto Gallino, Switzerland
Hiromichi Wada, Kyoto, Japan: Vascular endothelial growth factor-C and mortality in patients with suspected coronary artery disease

Anti-thrombotic Therapy during and after Coronary Intervention

Augusto Gallino, Switzerland
Doreen Tan, Singapore
Bernard MY Cheung, Hong Kong: Resolving the controversy on optimal duration of dual antiplatelet therapy after coronary intervention
Antoni Martinez-Rubio, Barcelona, Spain: DOAC in coronary artery disease
Isao Taguchi, Saitama, Japan: Optimal anti-thrombotic therapy after PCI

Governor’s Meeting

World Tobacco No Day Memorial Session:
Tobacco and heart disease

Keijiro Saku, Kyoto Japan
Tatsuya Morimoto, Shizuoka Japan
Speakers and Discussants:
Toyoaki Murohara, Aichi Japan: Tobacco and cardiovascular disease
Rei Goto, Tokyo Japan: Cost-benefit Effectiveness on Smoking Cessation
Lisa Demos, Australia: Pharmacotherapy and Australian initiatives for smoking cessation

Cardiac metabolism and mitochondria


Satoaki Matoba, Kyoto Japan
Hiroshi Kondo, Kyoto Japan
Osamu Yamaguchi, Ehime, Japan: Mitochondria degradation as a novel therapeutic target for heart failure
Masaya Tanno, Hokkaido, Japan: Regulation of mitochondrial GSK-3β activity by kinases, phosphatases and a deacetylase: a key determinant for mitochondrial permeability transition
Ippei Shimizu, Niigata Japan: The pathological role of brown adipose tissue dysfunction in cardio-metabolic disorders
Atsushi Hoshino, Kyoto Japan: Essential mitochondrial components to induce mitophagy